

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human LAP TGF-β1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody is specific for the LAP derived from the TGF-β1 precursor, but does not react with LAP from the TGF-β2 precursor.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived and Chinese hamster ovary cell line CHO-derived recombinant human LAP TGF-β1 Leu30-Ser390 Accession # P01137
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human LAP TGF-β1 (Catalog # 246-LP)
Immunocytochemistry	5-15 µg/mL	Immersion fixed human peripheral blood mononuclear cells
Neutralization	Measured by its ability to neutralize LAP TGF-β1 inhibition of TGF-β1 growth inhibition in the HT-2 mouse T cell line. Tsang, M. <i>et al.</i> (1995) Cytokine 7:389. The Neutralization Dose (ND ₅₀) is typically 0.4-2 µg/mL in the presence of 500 ng/mL Recombinant Human LAP TGF-β1 and 1 ng/mL TGF-β1.	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

TGF-β1 (transforming growth factor beta 1) and the closely related TGF-β2 and -β3 are members of the large TGF-β superfamily. TGF-β proteins are highly pleiotropic cytokines that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1-3). Human TGF-β1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (4). A furin-like convertase processes the proprotein within the trans-Golgi to generate an N-terminal 249 aa (aa 30-278) latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-β1 (aa 279-390) (4-6). Disulfide-linked homodimers of LAP and TGF-β1 remain non-covalently associated after secretion, forming the small latent TGF-β1 complex (4-8). Purified LAP is also capable of associating with active TGF-β with high affinity, and can neutralize TGF-β activity (9). Covalent linkage of LAP to one of three latent TGF-β binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (5-7). TGF-β activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins (5, 8). The LAP portion of human TGF-β1 shares 91%, 92%, 85%, 86% and 88% aa identity with porcine, canine, mouse, rat and equine TGF-β1 LAP, respectively, while mature human TGF-β1 portion shares 100% aa identity with porcine, canine and bovine TGF-β1, and 99% aa identity with mouse, rat and equine TGF-β1. Although different isoforms of TGF-β are naturally associated with their own distinct LAPs, the TGF-β1 LAP is capable of complexing with, and inactivating, all other human TGF-β isoforms and those of most other species (9). Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-β1 (10).

References:

1. Dunker, N. & K. Kriegstein (2000) *Eur. J. Biochem.* **267**:6982.
2. Wahl, S.M. (2006) *Immunol. Rev.* **213**:213.
3. Chang, H. *et al.* (2002) *Endocr. Rev.* **23**:787.
4. Derynck, R. *et al.* (1985) *Nature* **316**:701.
5. Dabovic, B. and D.B. Rifkin (2008) "TGF-β Bioavailability" in *The TGF-β Family*. Derynck, R. and K. Miyazono (eds): Cold Spring Harbor Laboratory Press, p. 179.
6. Brunner, A.M. *et al.* (1989) *J. Biol. Chem.* **264**:13660.
7. Miyazono, K. *et al.* (1991) *EMBO J.* **10**:1091.
8. Oklu, R. and R. Hesketh (2000) *Biochem. J.* **352**:601.
9. Miller, D.M. *et al.* (1992) *Mol. Endocrinol.* **6**:694.
10. Janssens, K. *et al.* (2003) *J. Biol. Chem.* **278**:7718.